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In the VALUE trial,1 new-onset diabetes arose in significantly fewer hypertensive patients on valsartan, an 
angiotensin receptor AT1 blocker (ARB), than on amlodipine, a metabolically neutral calcium-channel blocker, 
after a mean follow-up of 4.2 years. This finding confirms and extends the results of the Antihypertensive and 
Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)2 in which the incidence of diabetes was 
lower in hypertensive patients on lisinopril, an angiotensin converting enzyme (ACE) inhibitor, than on 
amlodipine. In ALLHAT, the between-group difference was even greater when lisinopril was compared with the 
diuretic chlorthalidone. 
The findings of a systematic review of the published work3 indicate, in seven large randomised clinical trials 
done in patients with arterial hypertension with cardiovascular prognosis as primary endpoints, a possible 
beneficial effect of blockade of the renin-angiotensin system on the frequency on new-onset type 2 diabetes 
(defined, however, using various criteria and analysed as a secondary endpoint or in post-hoc analysis). Overall, 
and after a mean follow up ranging from 3.7 to 6.1 years, 2502 new cases of diabetes (8%) were observed in the 
group of 33 103 patients who received treatment with ACE inhibitors or ARBs by comparison with 3601 of 36 
847 (10%) controls (figure). The findings of this analysis showed a mean weighed relative risk reduction of new 
diabetes of 22% (95% CI 18-25; p<0.0001) after inhibition of the renin-angiotensin system. No significant 
heterogeneity was observed between trials (p=0.07). The beneficial effect was significant and similar with ACE 
inhibitors (hazard ratio 0-78; p<0.0001) and with ARBs (0-79; p<0.0001), and observed whatever the 
comparator considered. The number needed to treat to avoid one new case of diabetes averaged 45 patients over 
about 5 years. A similar relative risk reduction in the frequency of diabetes after inhibition of the renin-
angiotensin system was reported in the CHARM-Overall programme,4 comparing the effects of candesartan with 
those of placebo in patients with congestive heart failure (hazard ratio 0.78, 95% CI 0.64-0.96; p=0.020). 
Inhibition of the renin-angiotensin system consistently and significantly reduces the incidence of type 2 diabetes 
mellitus in individuals with arterial hypertension and congestive heart failure. The underlying mechanisms seem 
complex and include effects of inhibition of the renin-angiotensin system on both insulin action and insulin 
secretion.5 Considering the pandemic of the disease, inhibition of the renin-angiotensin system deserves further 
attention among the strategies aimed at preventing type 2 diabetes mellitus. 
 
Figure: Meta-ana lysis of seven randomised clinical trials assessing the effect of inhibition of the 
reninangiotensin system on incidence of new diabetes in patients with arterial hypertension. 
ALLHAT(a)=comparison of lisinopril υs chlorthalidone. ALLHAT(b)=comparison of lisinopril υs amlodipine. χ2 
test for heterogeneity p=0.07. Test for overall effect ρ<0.0001. 
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